Scientists at MIT and Standford University have introduced a new method for activating the immune system to recognize and attack cancer cells, offering a potential way to expand the benefits of immunotherapy to a larger group of patients.
Their strategy centers on disabling a biological “brake” that tumors use to avoid immune detection. This mechanism is driven by glycans, which are sugar molecules displayed on the outer surface of cancer cells and which interfere with normal immune responses.
